Allosteric hemoglobin modifiers useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood
US5122539A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | May 20, 1991 |
| Grant date | Jun 16, 1992 |
| Priority date | — |
| Expiry date | May 20, 2011 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C271/58
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Compounds of the general structural formula: ##STR1## wherein X, Y and Z may each be CH.sub.2, NH, or O, R.sub.2-6 are either hydrogen, halogen, or a substituted or unsubstituted C.sub.1, C.sub.2, or C.sub.3 alkyl group and these moieties maybe the same or different, or alkyl moieties of aliphatic or aromatic rings incorporating two of the R.sub.2-6 sites, R.sub.7-8 are hydrogen, methyl, or ethyl groups and these moieties may be the same or different, or alkyl moieties as part of an aliphatic ring connecting R.sub.7 and R.sub.8, and R.sub.9 is a hydrogen, loweralkyl such as methyl, ethyl or propyl, or a salt cation such as sodium, potassium, or ammonium are useful for right-shifting hemoglobin towards a low oxygen affinity state. The compounds are capable of acting on hemoglobin in whole blood. In addition, the compounds can maintain the oxygen affinity in blood during storage and can restore the oxygen affinity of outdated blood.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.